RBR-2kmyfm尚未招募4 期
Follitropin Delta plus Menotropin for Ovarian Stimulation during In Vitro Fertilization treatments in patients at risk of ovarian poor response: a prospective clinical trial
Clinica Vidabemvinda0 个研究点开始时间: 2020年2月10日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- — 至 40Y（—）
- 性别
- Female
入选标准
- •Informed consent signed before starting the treatment cycle; Good physical and mental health; Pre-menopausal women aged at least 18 and at most 40 years of age when they sign the consent form and when they start the treatment cycle, in that order; Infertile women diagnosed with tubal, unexplained infertility, endometriosis stage I or II or whose partners have a male factor and are eligible for IVF or intracytoplasmic sperm injection (ICSI) using fresh or frozen semen from the partner or donated; Infertility of at least one year before the start of the study for women up to 37 years old and for at least 6 months for women aged 38 years or more (not applicable if there is already known tubal or male factor);
- •The cycle included should be the individual's first controlled ovarian stimulation cycle for IVF;Regular menstrual cycles lasting between 24 and 35 days, presumably ovulatory; Hysterosalpingography, hysteroscopy, hysterosonography or transvaginal ultrasound documenting uterus with anatomy compatible with pregnancy (that is, without evidence of submucosal or intramural uterine fibroids larger than three centimeters, polyps or congenital anomalies that are associated with reduced chances of pregnancy within one year before the start of the study);Transvaginal ultrasound documenting the presence of both ovaries in an accessible position for egg collection, without clear evidence of other normalities (that is, endometriomas larger than three centimeters or ovaries of very large volume that contraindicate the use of gonadotropins) and normal attachments (that is, without hydrosalpinx) within one year before the start of the study; Serum FSH levels in early follicular false (from the second to the fourth day of the cycle) between 1 IU per L and 15 IU per L, obtained within three months of the beginning of the study; Negative serologies for HIV, HTLV, Hepatitis B (surface antigen and anti-core), Hepatitis C and syphilis, within 6 months of the beginning of the study and Zika virus in the month of the beginning of the cycle; Body mass index between 17.5 and 32 kg per square meter (including both values) at the beginning of the study; Availability to accept a transfer of up to two blastocysts originating from the study cycle within one year after inclusion
排除标准
- •known stage III or IV endometriosis;
- •One or more follicles greater than or equal to 10 mm on the day the stimulation starts; History of recurrent miscarriage (three consecutive losses before 24 weeks, excluding ectopic pregnancy); Abnormal karyotype of the woman or partner or semen donor. In cases where the seminal analysis shows a concentration below one million sperm per mL, a Y chromosome microdeletion test with normal results is mandatory; Any significant systemic clinical disease (eg, insulin-dependent diabetes); Any known hereditary or acquired thrombobophilia; Active arterial or venous thromboembollism or severe thrombophlebitis, or history of these events; known porphyria; Any endocrine-metabolic disease (pituitary, adrenal, liver, pancreas and kidney) that may compromise participation in the study, with the exception of well-controlled thyroid disease; Presence of known anti-FSH antibodies (based on history and previous tests and not on tests performed during that study); Known tumors of ovary, breast, uterus, adrenal, pituitary or hypothalamus that contraindicate the use of gonadotropins; Impaired kidney or liver function; Current lactant; Abnormal vaginal bleeding without a definite cause; Abnormal cervical oncotic cytology within three years of the start of the study (unless already treated and resolved); Findings of gynecological exams that reduce the chance of pregnancy (congenital uterine malformations and retained intrauterine devices); Current pregnancy (negative pregnancy test documented at the beginning of the cycle) or contraindication for pregnancy; Current pelvic inflammatory disease; Use of fertility modifiers at the beginning of the study such as DHEA, pills, progestogens or estrogens; Use of hormonal medications (except for thyroid); Known history of chemotherapy (except for gestational trophoblastic neoplasia) or radiation therapy; Current or past drug and alcohol abuse within one year of starting the study (drinking more than 14 units of alcohol per week); Current or past smoking within three months of the start of the study (more than 10 cigarettes per day); Hypersensitivity to any of the inputs used in the study; Have already participated in the study; Use of drugs not yet registered within three months of the study
研究者
相似试验
进行中（未招募）
1 期
uteal phase ovarian stimulation with Follitropin delta and dydrogesteroneVolutary women who wish to donate their oocytesCTIS2024-513998-48-00niversitair Ziekenhuis Brussel50
进行中（未招募）
1 期
uteal phase ovarian stimulation with Follitropin delta and dydrogesteroneVolutary women who wish to donate their oocytesEUCTR2022-003049-37-BEZ Brussel50
已完成
不适用
Ovarian stimulation with follicle stimulating hormone (r-FSH) for women with high early follicular FSH and intra-uterine insemination (IUI) indicatioISRCTN14825568VU University Medical Centre (VUMC) (Netherlands)80
招募中
Unknown
A Comparative Study of the Efficacy and Safety of Follitropin Delta With Follitropin Alfa with Progestin Primed Ovarian Stimulation (PPOS) in Japanese Women Undergoing Assisted Reproductive Technology (ART)Primary and secondary infertilityJPRN-UMIN000049988Kamiya Ladies Clinic500
进行中（未招募）
1 期
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trialPre- and post-menopausal women with HR+/HER2- LABC or MBC whose disease has progressed to CDK4/6 inhibitor in combination with a hormonal therapy in the adjuvant or metastatic settingMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2024-513372-18-00Consorzio Oncotech168